Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Lowered to $200 at Barclays

April 25, 2024 3:31 AM
Barclays analyst Carter Gould lowered the price target on Biogen (NASDAQ: BIIB) to $200.00 (from $215.00) while maintaining a Equalweight rating.

Categories

Analyst PT Change

Next Articles